Últimas publicaciones en anticoagulación
Bienvenido al Med Info Alert. En la siguiente página podrás encontrar información de interés sobre anticoagulación, publicada en los meses de mayo y junio.
Fibrilación Auricular y Anticoagulación
Esquivias GB, et al. Clinical evolution of patients with AF and diabetes mellitus in the COVID-19 pandemic. REFADI Registry. REC: CardioClinics, 2023
Yokoyama Y, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: A meta-analysis. J Thorac Cardiovasc Surg. 2023
Teppo K, et al. Aortic Stenosis and Outcomes in Patients With Atrial Fibrillation: A Nationwide Cohort Study. J Am Heart Assoc. 2023
Rodilla E, et al. Patterns and outcomes of switching direct oral anticoagulants in non-valvular atrial fibrillation: A real-world experience from Spain. Rev Clin Esp (Barc). 2023
Komen JJ, et al. Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. Eur Heart J. 2022
Al-Hussainy N, et al. Safety and efficacy of direct oral anticoagulants in patients with anaemia and atrial fibrillation: an observational nationwide Danish cohort study. Eur Heart J Qual Care Clin Outcomes. 2022
Harrington J, et al. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. Circulation. 2023
PRADAXA, PRAXBIND Y OTROS AGENTES REVERSORES
Caldeira D, et al. Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY. Stroke. 2023
Menichelli D, et al. Minimizing drug-drug interactions between dabigatran and levetiracetam through clinical management: a case report. Eur Heart J Case Rep. 2023
Shaji A. et al. Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding. Perspect Clin Res. 2023
Keinath JJ, et al. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds. J Thromb Thrombolysis. 2023
van der Horst SFB, et al. Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes. Thromb Res. 2023
Romoli M, et al. Thrombolysis after dabigatran reversal: A nation-wide Italian multicentre study, systematic review and meta-analysis. Eur Stroke J. 2023
MÁS PUBLICACIONES
PC-ES-111208